Posted by Michael Wonder on 22 Jun 2021
Acrux receives approval from the FDA for its generic version of Jublia
22 June 2021 - Acrux is pleased to announce that the US FDA has granted approval of the Company’s generic version of Jublia (efinaconazole) 10% topical solution.
In June 2018, Acrux submitted an ANDA with a Paragraph IV patent certification to seek approval from the FDA to market a generic version of Jublia 10% topical solution, before the expiration of the Jublia listed patents in the Orange Book.
